UCT-MSC + Biomaterials
Crohn’s Disease
Key Facts
About Vitti Labs
Founded in 2021, Vitti Labs operates a dual business model combining a regulated tissue banking service with a therapeutic development pipeline. Its core manufacturing focuses on producing high-quality, ethically sourced HCT/Ps for clinical use, supported by AATB accreditation. Concurrently, the company is advancing a pipeline of investigational therapies targeting pulmonary, inflammatory, neurodegenerative, and other diseases, with several programs in clinical trials. This positions Vitti Labs at the intersection of regenerative medicine supply and novel biologic drug development.
View full company profileAbout Vitti Labs
Founded in 2021, Vitti Labs operates a dual business model combining a regulated tissue banking service with a therapeutic development pipeline. Its core manufacturing focuses on producing high-quality, ethically sourced HCT/Ps for clinical use, supported by AATB accreditation. Concurrently, the company is advancing a pipeline of investigational therapies targeting pulmonary, inflammatory, neurodegenerative, and other diseases, with several programs in clinical trials. This positions Vitti Labs at the intersection of regenerative medicine supply and novel biologic drug development.
View full company profileAbout Vitti Labs
Founded in 2021, Vitti Labs operates a dual business model combining a regulated tissue banking service with a therapeutic development pipeline. Its core manufacturing focuses on producing high-quality, ethically sourced HCT/Ps for clinical use, supported by AATB accreditation. Concurrently, the company is advancing a pipeline of investigational therapies targeting pulmonary, inflammatory, neurodegenerative, and other diseases, with several programs in clinical trials. This positions Vitti Labs at the intersection of regenerative medicine supply and novel biologic drug development.
View full company profile